Table 1 Patient and transplant characteristics

Gender, male/female

50 (50.0%)/50 (50.0%)

52 (51.0%)/50 (49.0%)

0.889

Patient age, median (range), years

35 (18–60)

35 (18–59)

0.916

WBC at diagnosis, median (range)

54.8 (1.3–463.0)

74.8 (1.7–385.1)

0.473

Cytogenetic risk^#

0.818

 Low risk

6 (6.0%)

4 (3.9%)

 Intermediate risk

80 (80.0%)

85 (83.3%)

 High risk

7 (7.0%)

5 (4.9%)

 Unknown

7 (7.0%)

8 (7.8%)

NPM1 mutation

0.575

 Concomitant

29 (29.0%)

26 (25.5%)

 Without

71 (71.0%)

76 (74.5%)

EBV serostatus

0.910

 D−/R-

21 (21.0%)

19 (18.6%)

 D+/R-

24 (24.0%)

28 (27.5%)

 D−/R+

20 (20.0%)

22 (21.6%)

 D+/R+

35 (35.0%)

33 (32.3%)

CMV serostatus

0.982

 D−/R−

7 (7.0%)

7 (6.9%)

 D+/R−

5 (5.0%)

4 (3.9%)

 D−R+

9 (9.0%)

10 (9.8%)

 D+/R+

79 (79.0%)

81 (79.4%)

Sorafenib pre-transplant

0.654

 Use

59 (59.0%)

57 (55.9%)

 No use

41 (41.0%)

45 (44.1%)

CR status at transplant

0.546

 ≥ CR2

21 (21.0%)

18 (17.6%)

 CR1

79 (79.0%)

84 (82.4%)

MRD at transplant

0.723

 Positive

31 (31.0%)

34 (33.3%)

 Negative

69 (69.0%)

68 (66.7%)

GVHD prophylaxis

0.512

 CsA+MTX+MMF

44 (44.0%)

39 (38.2%)

 CsA+MTX+ATG

8 (8.0%)

6 (5.9%)

 CsA+MTX+ATG+MMF

48 (48.0%)

57 (55.9%)

ATG use in the conditioning

0.405

 Use

44 (44.0%)

39 (38.2%)

 No use

56 (56.0%)

63 (61.8%)

Transplant modality

0.512

 MSD

44 (44.0%)

39 (38.2%)

 MUD

8 (8.0%)

6 (5.9%)

 HID

48 (48.0%)

57 (55.9%)

Donor sources

0.262

 PBSC

52 (52.0%)

45 (44.1%)

 PBSC+BM

48 (48.0%)

57 (55.9%)

Median CD34⁺cells per graft, 10⁶/kg (range)

6.3 (3.7–10.2)

6.1 (3.3–11.3)

0.746